Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting

Abstract

Background: This study examined real-world etanercept and adalimumab treatment patterns in patients with psoriasis, psoriatic arthritis, or both. Methods: This retrospective analysis utilized data from patients with psoriasis, psoriatic arthritis, or both from a large, US claims database. Outcome measures included persistence on index therapy; pauses (7–59 days) and gaps (≥60 days) in therapy; and rates of discontinuing, switching and restarting index therapy in nonpersistent patients. Results: Of 4,453 patients, 2,534 initiated etanercept and 1,919 initiated adalimumab. In psoriasis patients (n = 2,775), 46.4% and 56.8% on etanercept and adalimumab, respectively, were persistent for ≥12 months, 49.0% and 56.3% discontinued, 23.8% and 22.4% restarted and 14.9% and 11.3% switched index therapy within 12 months. In psoriatic arthritis patients (n = 1,197), 60.7% and 63.3% on etanercept and adalimumab, respectively, were persistent for ≥12 months, 48.3% and 51.6% discontinued, 25.8% and 20.0% restarted and 16.5% and 17.9% switched index therapy. In patients with both (n = 481), 58.1% and 59.6% on etanercept and adalimumab, respectively, were persistent for ≥12 months, 42.7% and 63.2% discontinued, 24.3% and 12.6% restarted and 21.4% and 15.8% switched index therapy. Conclusions: Treatment modifications were common in patients with psoriasis, psoriatic arthritis, or both within 12 months of initiating etanercept or adalimumab.

Key words::

• TNF-inhibitors
• psoriasis
• psoriatic arthritis
• switch
• restart
• discontinue

Acknowledgments

We thank Julie Wang of Amgen, Inc. and Julia R. Gage on behalf of Amgen, Inc. for assistance with writing the manuscript.

Declaration of interests

Machaon Bonafede and Barbara H. Johnson are employed by Truven Health Analytics (formerly the Healthcare business of Thomson Reuters), which received funds from Amgen, Inc. to conduct this study. Kathleen M. Fox is a consultant for Amgen, Inc. Crystal Watson is a former employee and holds shares in Amgen, Inc. Shravanthi R. Gandra is an employee and shareholder of Amgen, Inc.